ClinicalTrials.gg
Sign In
RecruitingNCT07625202Updated Jun 4, 2026

Creatine Supplementation During GLP-1a Therapy

An interventional study of Dietary supplementation during a 12 week resistance-training program (creatine) and Dietary supplementation during a 12 week resistance-training program (placebo) in Sarcopenia, sponsored by University of Saskatchewan. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by University of Saskatchewan · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.

Read the detailed description

GLP-1 receptor agonists are highly effective for weight loss and increasing in popularity for those trying to lose weight. One concern with these medications is the potential for loss of lean tissue mass during rapid weight loss. This may affect strength and functional performance in people taking these medications. Resistance-training helps to offset loss of muscle mass during weight loss. Supplementation with creatine monohydrate is also effective for improving muscle mass and strength. The purpose of this pilot study is to determine the effectiveness of creatine supplementation during a resistance training program in people who are starting GLP-receptor agonist medication for preventing loss of lean tissue mass and functional performance. The investigators will randomize 40 people who are starting GLP-1 agonists to receive either 10g per day creatine or placebo during a resistance-training program (i.e., resistance-training three days per week for 12 weeks). It is hypothesized that participants on the creatine supplement will have superior maintenance of lean tissue mass and function performance compared to participants taking placebo.

02

Conditions studied

  • Sarcopenia

Browse trials for

03

In context

Sarcopenia

1,329 studies on the registry are indexed under Sarcopenia; 420 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 855 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

University of Saskatchewan is the lead sponsor of 243 studies on the registry; 34 are open to participants now.

Browse University of Saskatchewan studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Starting GLP-1 agonist therapy
  • 18 years of age or older

Exclusion criteria

Exclusion Criteria:

  • Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Creatine

    10 grams per day creatine

    Dietary Supplement: Dietary supplementation during a 12 week resistance-training program (creatine)

  • Placebo comparator
    Placebo

    Placebo (maltodextrin)

    Dietary Supplement: Dietary supplementation during a 12 week resistance-training program (placebo)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in sit to stand performance (number of times)

    change in number of times sitting and standing in 30 seconds

    Time frame: 12 weeks

Secondary outcomes

  1. Change in 10 meter gait speed (m/s)

    change in walking speed over 10 meters

    Time frame: 12 weeks

  2. Change in timed up and go (m/s)

    change in time to stand up, walk 3m, turn, around, walk 3 m and sit down

    Time frame: 12 weeks

  3. Change in lean tissue mass (kg)

    Change in lean tissue mass as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

  4. Change in fat mass (kg)

    Change in fat mass as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

  5. Change in whole body bone mineral density (g/cm squared)

    Change in bone mineral density as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

  6. Change in femoral neck bone mineral density (g/cm squared)

    Change in bone mineral density as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

  7. Change in total hip bone mineral density (g/cm squared)

    Change in bone mineral density as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

  8. Change in lumbar spine bone mineral density (g/cm squared)

    Change in bone mineral density as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

  9. Change in hip section modulus (cm-cubed)

    Change in hip section modulus as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

  10. Change in muscle thickness of the biceps (cm)

    Change in muscle thickness measured by ultrasound

    Time frame: 12 weeks

  11. Change in muscle thickness of the quadriceps (cm)

    Change in muscle thickness measured by ultrasound

    Time frame: 12 weeks

  12. Change in bench press strength (kg)

    change in upper body strength measured by predicted one repetition maximum

    Time frame: 12 weeks

  13. Change in leg extension strength (kg)

    Change in lower body strength measured by predicted one repetition maximum

    Time frame: 12 weeks

  14. Change in hip buckling ratio (ratio)

    Change in hip buckling ratio as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

  15. Change in hip cross-sectional area (cm-squared)

    Change in hip cross-sectional area as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

  16. Change in hip cortical thickness (cm)

    Change in hip cortical thickness as determined by dual energy x-ray absorptiometry

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 492 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 12 months is below that.

Counting every sponsor, half of 503 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2026
First posted
Jun 4, 2026
StartActual
May 25, 2026
Primary completionEst.
May 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07625202
Lead sponsor
University of Saskatchewan
Responsible party
Phil Chilibeck (Professor, University of Saskatchewan) — Principal investigator
First posted
Jun 4, 2026
Start date
May 25, 2026
Primary completion
May 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jun 4, 2026

Study contacts

Philip D Chilibeck, PhD
Contact
phil.chilibeck@usask.ca
306-966-1072
Philip Chilibeck, PhD
principal investigator · University of Saskatchewan

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Creatine

Other studies in this condition

Sarcopenia →

Other studies from this sponsor

University of Saskatchewan →

Start the discussion